Details

Last Funding Type

Series A

Industries

Biotechnology,Health Care,Medical,Pharmaceutical

Founded date

Jun 1, 2017

Number Of Employee

11 - 50

Operating Status

Active

Kangjing Bio focuses on the research and development of innovative drugs for the immunotherapy of autoimmune diseases and tumors. A round of financing of nearly 100 million yuan has been completed. This round of financing was jointly led by Sequoia China and Yahui Investment, followed by Fuchuang Investment and Renyou Investment. For this transaction, Hejun Capital and Chenrui Capital acted as financial advisors. This round of financing will be mainly used for phase I clinical trials of complement inhibitors under research on new targets, the advancement of other pipeline drugs, and the further consolidation of the application of innovative drug research and development platforms based on the complement system.